How Boston Scientific scaled AI across global service operations

85% of enterprise AI pilots never reach full production. According to Gartner's 2025 AI deployment survey, the leading cause isn't the technology. It's everything surrounding it: data quality, organizational readiness, and the discipline to execute without losing momentum between phases.

The Boston Scientific program is one of the clearest examples I've seen of what it looks like when those conditions are met.

Why most AI pilots stall before reaching production

The pattern is familiar. A pilot delivers promising results. Stakeholders are encouraged. And then the program quietly loses steam as it scales, caught between data quality gaps, shifting priorities, and the difficulty of translating a controlled pilot into a production system that thousands of people rely on every day.

What separates programs that reach production from those that don't is rarely a technology decision. It's a readiness decision.

Phase 1: piloting AI in a North America TAC environment

In August 2025, Boston Scientific launched a focused Phase 1 pilot with Neuron7 across two product lines within their North America Technical Assistance Center. From the start, what set this apart was how the team engaged: not just adopting the platform, but testing it, questioning it, and gradually making it part of daily workflows.

That kind of engagement is the result of clear alignment on what success looks like at the field level, and consistent leadership support that didn't require re-selling the vision at every checkpoint. When Phase 1 concluded, the question wasn't whether to continue. It was how to scale.

Phase 2: what a clean enterprise AI launch looks like

Phase 2 went live in May 2026, extending Neuron7 across all North America TAC users.

Zero critical issues during two weeks of hyper care.

That outcome reflects three things: disciplined UAT, strong collaboration between engineering and QA on both sides, and a commitment to data quality that was built into the program from the beginning. Neuron7's AI Readiness Platform formalizes exactly that commitment, providing a continuous score for service data quality so that as a program scales, every new phase starts from a foundation teams can trust rather than discovering gaps after deployment.

What made this work where others stall

Three factors consistently separate programs that scale from those that don't.

1. Clear definition of field-level success. Not executive KPIs alone, but the specific outcomes individual technicians and TAC engineers could measure day to day.
2. Consistent leadership engagement. The kind that keeps a program moving without requiring re-justification at every milestone.
3. Visible execution cadence. Blockers surfaced early, progress tracked against clear milestones, no assumption that momentum sustains itself.

None of these are glamorous. But in my experience they are almost always the deciding factor.

What comes next: from reactive resolution to predictive service

Based on strong adoption and outcomes across North America, Boston Scientific is now expanding Neuron7 across their global service organization, bringing 20 additional product lines into scope and extending deployment across LATAM, Europe, and Asia. The program will ultimately support every Field Service Engineer and Technical Assistance Center resource across all regions.

At that scale, the platform's focus also shifts. The reactive phase, resolving issues faster when they occur, becomes the foundation for what comes next. Neuron7's Predictive Service Intelligence maps failure patterns across the installed base and identifies what is likely to fail before a dispatch is ever needed, allowing field teams to address issues during a scheduled visit rather than respond to an emergency one. For an organization operating at the scale Boston Scientific is building toward, that shift represents a meaningful change in what field service can deliver for customers.

This is no longer a pilot. It is a full-scale service transformation, built thoughtfully and executed with discipline at every step.

To the Boston Scientific team: thank you for the partnership, the rigor, and the follow-through. It has been a privilege to build this together.

‍

Read next: How TransLogic stopped losing expert knowledge when their best technicians retired. What Happens When Kevin Leaves

--

About Boston Scientific

Boston Scientific is a global medical device manufacturer that develops, manufactures, and services technologies used to diagnose and treat conditions across cardiology, endoscopy, urology, neuromodulation, and more. With more than 50,000 employees and operations spanning over 100 countries, the company supports a large distributed field service and technical assistance organization where device uptime and resolution accuracy directly affect patient outcomes.

About Neuron7

Neuron7 is the service decision layer for complex service organizations, capturing expert knowledge, delivering step-by-step resolution guidance, and predicting failures before customers experience them. Purpose-built for medical devices, high-tech equipment, industrial systems, and telecom, Neuron7 delivers 90%+ resolution accuracy within existing CRM platforms. Deployed by global leaders including NCR Atleos, Keysight Technologies, Karl Storz, Ciena, and TK Elevator.